Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.

Slides:



Advertisements
Similar presentations
Monte Carlo simulations and bioequivalence of antimicrobial drugs NATIONAL VETERINARY S C H O O L T O U L O U S E July 2005 Didier Concordet.
Advertisements

A 23 Variability in the Size of the Fluoroquinolone AUC/MIC for Antibacterial Effect in S.aureus: Impact for Clinical Breakpoints A. R. Noel, K.E. Bowker,
Scott Butler Infection Innovative Medicines Group AstraZeneca R&D, Boston CPTR Workshop, 2012 Arlington, VA AZD5847 Oxazolidinone for the treatment of.
Pharmacodynamics of MASKO Compounds (Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones) William A. Craig, MD University of Wisconsin.
Animal Model PK/PD: A Tool for Drug Development
Pharmacodynamics and the Dosing of Antibacterials
April 1st, 2006ISAP-ECCMID PK/PD Workshop - Nice, France 1 PK/PD modeling : Clinical Implications J.W. Mouton Dept Medical Microbiology, Canisius Wilhelmina.
Eccmid 2003 Aminoglycosiden bij neonaten Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton Relationship between bacterial killing,
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
The Relationship between Daptomycin (DAP) Free drug AUC/MIC, Antibacterial effect (ABE) and Emergence of Resistance (EoR) in S.aureus. KE Bowker, AR Noel,
Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Pharmacodynamics of Antibiotics
The (important) role of the pharmacist in the handling of COPD - H. Lode - Free University Berlin.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
WHICH PK-PD MEASURE FOR WHICH DRUG? Sujata M. Bhavnani, Pharm.D, MS Institute for Clinical Pharmacodynamics Ordway Research Institute Latham, New York.
PK/PD: New Microbial Diseases and Model Systems Tawanda Gumbo, MD Associate Professor of Medicine, Division of Infectious Diseases, University of Texas.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Synergism : what does it mean? JW Mouton Dept Medical Microbiology Canisius Wilhelmina Hospital Nijmegen, The Netherlands.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Effect of Adequate Antimicrobial Therapy For Bloodstream Infections on Mortality
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
Application of PK/PD modeling for optimization of linezolid therapy Julia Zayezdnaya Zack.
PK/PD Dosing in Critical Care Jim Fenner Pharm D BCPS.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
PK/PD - ICC - Manila, June 5th, The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul.
Use of in vitro models to study the emergence of resistance Professor Inga Odenholt Department of Infectious Diseases University hospital, Malmö Sweden.
William A. Craig Symposium ISAP Research Meeting PK/PD and Genomics David Andes University of Wisconsin.
A Pharmacodynamic Model for Cefprozil against Haemphilus influenzae in an in vitro Infection Model across Multiple Regimens Olanrewaju O. Okusanya, Pharm.D,
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Preclinical Models to Support Dosage Selection
Pharmacokinetics of Antimicrobials in Animals: Lessons Learned William A. Craig, M.D. University of Wisconsin-Madison.
Population PK-PD Modeling of Anti-Infective Agents
The Endpoint from a Resistance Point of View A Symposium to Honor the Career of William A. Craig, M.D. George Drusano, M.D. Co-Director Ordway Research.
The General Concepts of Pharmacokinetics and Pharmacodynamics
Ten Years After: Where is ISAP?
Methods for detecting resistance Goal: To determine whether organism expresses resistances to agents potentially used for therapy Designed to determine.
Issues in testing regimens containing multiple novel agents I. Preclinical Testing Jacques Grosset Johns Hopkins University School of Medicine, Baltimore,
Pharmacodynamics of Antifungals
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
1 Developments in pK/pD: optimising efficacy & prevention of resistance A critical review of pK/pD in in vitro models Alasdair MacGowan Bristol Centre.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
Pk/Pd modelling : Clinical Implications
PK/PD: TOWARDS DEFINITIVE CRITERIA PK/PD in clinical Practice: new level of PK/PD Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy,
The General Concepts of Pharmacokinetics and Pharmacodynamics
JWM Grindelwald Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices.
Improvement in Dose Selection Through Clinical PK/PD in Antimicrobial Drug Development: Perspective of an Industry PK/PD Scientist Gregory A. Winchell,
Pharmacodynamics of Antimicrobials William A. Craig, M.D. University of Wisconsin-Madison.
Effects of omadacycline on gut microbiota populations and Clostridium difficile germination, proliferation and toxin production in an in vitro model of.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
MACROLIDES: pharmacokinetics and pharmacodynamics
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
International Society for Anti-infective Pharmacology (ISAP)
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.
Towards clinical Applications of PK-PD in specific situations
Evaluation of the Efficacy of Intramuscular (IM) Administration of Ceftaroline (CPT) Against a Methicillin-Resistant Staphylococcus aureus (MRSA) Strain.
PK/PD: from theory to applications in the real world...
Optimizing Aminoglycoside Use
Doripenem vs Meropenem: a summary of International and Belgian published data Françoise Van Bambeke, Unité de Pharmacologie cellulaire et moléculaire Louvain.
W.W. Hope, G.L. Drusano  Clinical Microbiology and Infection 
Françoise Van Bambeke, Dr Sc. Pharm, Agr. Ens. Sup.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
Thomas P. Lodise, PharmD, G.L. Drusano, MD  Critical Care Clinics 
Pharmacokinetics and pharmacodynamics of fluoroquinolones
Pharmacodynamic indices in targeting therapy of critical infections
M.R. Jacobs  Clinical Microbiology and Infection 
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach  J.W. Mouton, D.F.J. Brown, P. Apfalter, R. Cantón,
Presentation transcript:

Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton

Lowest concentration with no visible growth after 18 hour incubation MIC MIC = 2 mg/L ixafloxacin 500 mg PK

Pharmacokinetic parameter MIC Thus, to guide therapeutic choices we have to: –Establish a relationship between the MIC in vitro and concentrations in vivo (dosing regimens) –Determine which dosing regimens are optimal in relation to the MIC

MIC PEAK AUC TIME > MIC AUC and Dose are usually linearly related

PK/PD Neutropenic mouse thigh model Various doses and dosing regimens (q1 to q24) Outcome parameter: cfu counts after 24 h Plot PD parameter (AUC, Peak T>MIC) to effect

K. pneumoniae, imipenem Based on data from Craig

For K.pneumoniae, there is no clear relation between total daily dose of imipenem and efficacy in an in vivo model of infection

K. pneumoniae, imipenem Based on data from Craig

For beta-lactams, there is a direct relation between Time > MIC and efficacy

Relationship between T>MIC, Peak, AUC and effect of levofloxacin for S. pneumoniae in mice. Each dot represents one mouse / dosingregimen. Based on data from Scaglione & Mouton, 2001, 2003

Fig 2. levofloxacin ceftazidim Andes IJAA 2002

T>MICAUC PenicillinsAminoglycosides CephalosporinsFluoroquinolones CarbapenemsMetronidazole MonobactamsDaptomycin TribactamsKetolides Clindamycin?Macrolides? Azithromycin Streptogramins GlycopeptidesGlycylcyclines? Oxazolidinones Tetracyclines Azoles Relationship Pharmacokinetic Parameter and Effect

Relationship AUC and effect What has the MIC to do with this? Scaglione et al., AAC 2003

Andes et al ISHAM 2003 Now, what is the Effect of the mic in relation tot the dose? (or AUC) ?

Pharmacodynamic index Pharmacokinetic parameter MIC 'Normalizing pk/pd relationships'

Andes et al ISHAM 2003 (AUC)

Thus, 2 factors influence the value of the pk/pd index: Errors/variation in the MIC Pharmacokinetic variation

The MIC

The MIC is a result of : kill over time (kill rate) by the antibiotic growth over time (growth rate) for a certain number of micro-organisms (the inoculum) MIC AT STATIC CONCENTRATIONS

Growth and/or kill rate dependent : –strain, species –medium composition, brand –MH, supplements, ISO –number of bacteria –inoculum – (CLSI) vs 10 5 (BSAC) –temperature (35 o vs 37 o ) –growth phase –CO 2 –etc.

Mouton, icaac 2000

The MIC of the control strain should be within one two-fold dilution of the expected MIC A reference MIC method has been described by ISO/CEN Accepted by memberstates, pending minor adjustments ALL METHODS USED UN THE FUTURE SHOULD BE VALIDATED AGAINST THIS METHOD

Kahlmeter et al, JAC 2003

The reproducibility of the MIC is within 2 2fold dilutions. The variation introduced in the AUC/MIC and Peak/MIC values by the MIC is there for at least 0.5 tot 2 x the pk/pd index value!

SC= The concentration of antimicrobial at which growth equals kill, i.e. no net growth or kill at a certain point in time =NOT equal to MIC (which includes time) Distinguish between MIC in vitro and in vivo. Mouton & Vinks Clin Pharmacokinet : MIC vs SC (Stationary Concentration)

MIC MISCONCEPTION: 'Drug is active for a prolonged period of time, and remains above the MIC long enough to…. The SC may be lower or higher than the MIC, depending on its kill kinetics In general the SC is lower, especially for concentration dependent drugs Mouton & Vinks Clin Pharmacokinet :201-10

PHARMACOKINETIC parameters

Definition :The Area under the Concentration-time curve over 24 hours. Note: ….. It should be stated how the AUC is determined : based on (log) linear trapezoideal rule, based on clearance, or based on microconstants. Dimensions : concentration x time e.g. mg.h/L or  g.h /mL Mouton et al, J Antmicrob Chemother Available from ISAP site

AUC 0-24 = 3033 AUC inf = 5100 AUC 0-24 sd = 1361 AUC inf sd =1700 Mg.h/L

WHICH AUC? AUC 0-24h or AUC  Steady State? (log) trapezodeal rule? Derived ? (A/  +B/  or other)

Definition : The area under the concentration-time curve over 24 hours in steady state divided by the MIC. …. Note : ….For unbound fraction of the drug, use fAUC/MIC Dimensions : no dimensions Mouton et al, J Antmicrob Chemother 2005 Available from ISAP site AUC/MIC

Definition :The Area under the inhibitory curve over 24 hours. Note: the AUIC should be reserved for those cases where actual inhibitory titers have been measured and used in the calculations. The AUIC is not equal to the AUC/MIC. See also Flaherty et al, AAC 1988;32(12): ; Hyatt JM et al AAC 1994;38(12):2730-7; Occhipinti DJ et al, AAC 1997;41(11): Dimensions : none AUIC Mouton et al, J Antmicrob Chemother 2005 Available from ISAP site

Peak/MIC Definition : the peak level divided by the MIC. Dimensions : no dimensions. Mouton et al, J Antmicrob Chemother 2005 Available from ISAP site

WHICH PEAKLEVEL? After the 1st, 2nd or later dose? If more than one compartment, the peak level in compartment 1, 2 or even 3?

Scaglione et al, AAC 2003

Time > MIC Definition : the % of time above the MIC over a period of 24 hours. Note : if the period is other than 24 h, this should be stated explicitly. Dimensions : %. Mouton et al, J Antmicrob Chemother 2005 Available from ISAP site

Concentration-time profile of beta-lactam Vd = 20 L, Ka = 1.2 h -1, Ke = 0.3 h -1

Monte Carlo Simulation of beta-lactam Vd = 20 L, Ka = 1.2 h -1, Ke = 0.3 h -1, VC=20% 4h 10h Mouton, Int J Antimicrob Agents april 2002

For all indices : how are they determined how are they calculated what is the error? Only when these questions have been answered do we know the true impact and value of the index.